|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
At the authors' high-volume center, with increased surgeon and institutional experience over time, perioperative and oncologic outcomes have improved significantly for patients undergoing CRS/HIPEC for PC.
|
31222683 |
2020 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
In general, cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is standard of care for peritoneal carcinomatosis (PC) from mucinous appendiceal tumors; however, in PC from GCA, data are limited and the role of CRS/HIPEC is controversial.
|
31646450 |
2020 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
For patients with peritoneal carcinomatosis undergoing cytoreductive surgery with heated intraperitoneal chemotherapy (CRS/HIPEC), incomplete cytoreduction (CCR2/3) confers morbidity without survival benefit.
|
31602579 |
2020 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is unclear what benefit CRS/HIPEC might have for PC from uncommon etiologies, therefore we sought to describe local practice patterns and evaluate overall survival (OS).
|
30760409 |
2019 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent advances, specifically cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), offer advantages compared to the traditional therapeutic approach of systemic chemotherapy in the treatment of peritoneal carcinomatosis from mucinous appendiceal neoplasms (MAN).
|
30610247 |
2019 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we report our experience of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) in patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC), focusing on the factors affecting survival.
|
30917826 |
2019 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has been proven effective in select patients with peritoneal carcinomatosis (PC) from CRC, although it has not been evaluated specifically in patients < 50 years.
|
30643994 |
2019 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients diagnosed with PC due to appendiceal (AC), colorectal (CRC), and gastric cancer (GC) undergoing CRS/HIPEC 2007-2016 were included.
|
30650185 |
2019 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surgical relevance Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) improves survival of selected patients with colorectal peritoneal carcinomatosis, but recurrence is common.
|
29341165 |
2018 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among the 45 patients, CRS was mainly performed by laparotomy (n = 42), and only three patients with limited PC underwent laparoscopic CRS.
|
28562119 |
2018 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is unknown if there is a Peritoneal Carcinomatosis Index (PCI) upper limit above which a complete CRS/HIPEC does not assure long-term survival.
|
29288288 |
2018 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
A prospective database of all patients undergoing CRS-HIPEC for peritoneal carcinomatosis between 2004 and 2015 was queried for 90-day morbidity and mortality and survival.
|
28838265 |
2018 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current series validates time interval between cytoreductions as a major surrogate of tumor biology in selection of patients with recurrent peritoneal surface malignancies for repeat CRS/HIPEC.
|
28608388 |
2017 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a treatment option for peritoneal surface malignancies.
|
27913947 |
2017 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
We look at the incidence of acute kidney injury (AKI) in patients who have received cisplatin during CRS-HIPEC in the treatment of peritoneal carcinomatosis from an ovarian primary, and identify possible peri-operative risk factors.
|
28540777 |
2017 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identifying patients earlier who are either at risk for, or who have recently developed PC may provide them with additional treatment options such as CRS/HIPEC.
|
28415645 |
2017 |
|
Carcinomatosis of peritoneal cavity
|
0.100 |
Biomarker
|
disease |
BEFREE |
ASA class 4, major morbidity, and likely dependent functional status are independent predictors of FTR following CRS/HIPEC to treat peritoneal carcinomatosis.
|
28624046 |
2017 |